Selected research
Industry Research
AAV Gene Therapy Injection Industry Research Report 2026
Market perspective
The global AAV Gene Therapy Injection market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the AAV Gene Therapy Injection market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the AAV Gene Therapy Injection market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the AAV Gene Therapy Injection market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of AAV Gene Therapy Injection include Avexis/Novartis (Zolgensma), BioMarin (Roctavian), CSL/uniQure (Hemgenix&Glybera), PTC Therapeutics (Upstaza), Sarepta Therapeutics (Elevidys), Spark/Roche (Luxturna), Pfizer, Suzhou NoJieBeig (Pipeline) and Belief BioMed (Pipeline) and among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global AAV Gene Therapy Injection market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to AAV Gene Therapy Injection.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
AAV Gene Therapy Injection Market by Company
Avexis/Novartis (Zolgensma)
BioMarin (Roctavian)
CSL/uniQure (Hemgenix&Glybera)
PTC Therapeutics (Upstaza)
Sarepta Therapeutics (Elevidys)
Spark/Roche (Luxturna)
Pfizer
Suzhou NoJieBeig (Pipeline)
Belief BioMed (Pipeline)
Beijing Innovikang (Pipeline)
AAV Gene Therapy Injection Segment by Type
scAAV9 Vector
AVV5 Vector
AVV2 Vector
AAVrh74 Vector
AAV Gene Therapy Injection Segment by Application
Ophthalmic Diseases
Hemophilia
Spinal Muscular Atrophy (SMA)
Duchenne Muscular Dystrophy (DMD)
Others
AAV Gene Therapy Injection Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global AAV Gene Therapy Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of AAV Gene Therapy Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of AAV Gene Therapy Injection.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of AAV Gene Therapy Injection companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- scAAV9 Vector
- AVV5 Vector
- AVV2 Vector
- AAVrh74 Vector
Applications
- Ophthalmic Diseases
- Hemophilia
- Spinal Muscular Atrophy (SMA)
- Duchenne Muscular Dystrophy (DMD)
- Others
Companies covered
- Avexis/Novartis (Zolgensma)
- BioMarin (Roctavian)
- CSL/uniQure (Hemgenix&Glybera)
- PTC Therapeutics (Upstaza)
- Sarepta Therapeutics (Elevidys)
- Spark/Roche (Luxturna)
- Pfizer
- Suzhou NoJieBeig (Pipeline)
- Belief BioMed (Pipeline)
- Beijing Innovikang (Pipeline)
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 AAV Gene Therapy Injection by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 scAAV9 Vector
- 2.2.3 AVV5 Vector
- 2.2.4 AVV2 Vector
- 2.2.5 AAVrh74 Vector
- 2.3 AAV Gene Therapy Injection by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Ophthalmic Diseases
- 2.3.3 Hemophilia
- 2.3.4 Spinal Muscular Atrophy (SMA)
- 2.3.5 Duchenne Muscular Dystrophy (DMD)
- 2.3.6 Others
- 2.4 Assumptions and Limitations
3 AAV Gene Therapy Injection Breakdown Data by Type
- 3.1 Global AAV Gene Therapy Injection Historic Market Size by Type (2021-2026)
- 3.2 Global AAV Gene Therapy Injection Forecasted Market Size by Type (2027-2032)
4 AAV Gene Therapy Injection Breakdown Data by Application
- 4.1 Global AAV Gene Therapy Injection Historic Market Size by Application (2021-2026)
- 4.2 Global AAV Gene Therapy Injection Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global AAV Gene Therapy Injection Market Perspective (2021-2032)
- 5.2 Global AAV Gene Therapy Injection Growth Trends by Region
- 5.2.1 Global AAV Gene Therapy Injection Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 AAV Gene Therapy Injection Historic Market Size by Region (2021-2026)
- 5.2.3 AAV Gene Therapy Injection Forecasted Market Size by Region (2027-2032)
- 5.3 AAV Gene Therapy Injection Market Dynamics
- 5.3.1 AAV Gene Therapy Injection Industry Trends
- 5.3.2 AAV Gene Therapy Injection Market Drivers
- 5.3.3 AAV Gene Therapy Injection Market Challenges
- 5.3.4 AAV Gene Therapy Injection Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top AAV Gene Therapy Injection Players by Revenue
- 6.1.1 Global Top AAV Gene Therapy Injection Players by Revenue (2021-2026)
- 6.1.2 Global AAV Gene Therapy Injection Revenue Market Share by Players (2021-2026)
- 6.2 Global AAV Gene Therapy Injection Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of AAV Gene Therapy Injection Head Office and Area Served
- 6.4 Global AAV Gene Therapy Injection Players, Product Type & Application
- 6.5 Global AAV Gene Therapy Injection Manufacturers Established Date
- 6.6 Global AAV Gene Therapy Injection Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America AAV Gene Therapy Injection Market Size (2021-2032)
- 7.2 North America AAV Gene Therapy Injection Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America AAV Gene Therapy Injection Market Size by Country (2021-2026)
- 7.4 North America AAV Gene Therapy Injection Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe AAV Gene Therapy Injection Market Size (2021-2032)
- 8.2 Europe AAV Gene Therapy Injection Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe AAV Gene Therapy Injection Market Size by Country (2021-2026)
- 8.4 Europe AAV Gene Therapy Injection Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific AAV Gene Therapy Injection Market Size (2021-2032)
- 9.2 Asia-Pacific AAV Gene Therapy Injection Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific AAV Gene Therapy Injection Market Size by Country (2021-2026)
- 9.4 Asia-Pacific AAV Gene Therapy Injection Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America AAV Gene Therapy Injection Market Size (2021-2032)
- 10.2 South America AAV Gene Therapy Injection Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America AAV Gene Therapy Injection Market Size by Country (2021-2026)
- 10.4 South America AAV Gene Therapy Injection Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa AAV Gene Therapy Injection Market Size (2021-2032)
- 11.2 Middle East & Africa AAV Gene Therapy Injection Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa AAV Gene Therapy Injection Market Size by Country (2021-2026)
- 11.4 Middle East & Africa AAV Gene Therapy Injection Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Avexis/Novartis (Zolgensma)
- 12.1.1 Avexis/Novartis (Zolgensma) Company Information
- 12.1.2 Avexis/Novartis (Zolgensma) Business Overview
- 12.1.3 Avexis/Novartis (Zolgensma) Revenue in AAV Gene Therapy Injection Business (2021-2026)
- 12.1.4 Avexis/Novartis (Zolgensma) AAV Gene Therapy Injection Product Portfolio
- 12.1.5 Avexis/Novartis (Zolgensma) Recent Developments
- 12.2 BioMarin (Roctavian)
- 12.2.1 BioMarin (Roctavian) Company Information
- 12.2.2 BioMarin (Roctavian) Business Overview
- 12.2.3 BioMarin (Roctavian) Revenue in AAV Gene Therapy Injection Business (2021-2026)
- 12.2.4 BioMarin (Roctavian) AAV Gene Therapy Injection Product Portfolio
- 12.2.5 BioMarin (Roctavian) Recent Developments
- 12.3 CSL/uniQure (Hemgenix&Glybera)
- 12.3.1 CSL/uniQure (Hemgenix&Glybera) Company Information
- 12.3.2 CSL/uniQure (Hemgenix&Glybera) Business Overview
- 12.3.3 CSL/uniQure (Hemgenix&Glybera) Revenue in AAV Gene Therapy Injection Business (2021-2026)
- 12.3.4 CSL/uniQure (Hemgenix&Glybera) AAV Gene Therapy Injection Product Portfolio
- 12.3.5 CSL/uniQure (Hemgenix&Glybera) Recent Developments
- 12.4 PTC Therapeutics (Upstaza)
- 12.4.1 PTC Therapeutics (Upstaza) Company Information
- 12.4.2 PTC Therapeutics (Upstaza) Business Overview
- 12.4.3 PTC Therapeutics (Upstaza) Revenue in AAV Gene Therapy Injection Business (2021-2026)
- 12.4.4 PTC Therapeutics (Upstaza) AAV Gene Therapy Injection Product Portfolio
- 12.4.5 PTC Therapeutics (Upstaza) Recent Developments
- 12.5 Sarepta Therapeutics (Elevidys)
- 12.5.1 Sarepta Therapeutics (Elevidys) Company Information
- 12.5.2 Sarepta Therapeutics (Elevidys) Business Overview
- 12.5.3 Sarepta Therapeutics (Elevidys) Revenue in AAV Gene Therapy Injection Business (2021-2026)
- 12.5.4 Sarepta Therapeutics (Elevidys) AAV Gene Therapy Injection Product Portfolio
- 12.5.5 Sarepta Therapeutics (Elevidys) Recent Developments
- 12.6 Spark/Roche (Luxturna)
- 12.6.1 Spark/Roche (Luxturna) Company Information
- 12.6.2 Spark/Roche (Luxturna) Business Overview
- 12.6.3 Spark/Roche (Luxturna) Revenue in AAV Gene Therapy Injection Business (2021-2026)
- 12.6.4 Spark/Roche (Luxturna) AAV Gene Therapy Injection Product Portfolio
- 12.6.5 Spark/Roche (Luxturna) Recent Developments
- 12.7 Pfizer
- 12.7.1 Pfizer Company Information
- 12.7.2 Pfizer Business Overview
- 12.7.3 Pfizer Revenue in AAV Gene Therapy Injection Business (2021-2026)
- 12.7.4 Pfizer AAV Gene Therapy Injection Product Portfolio
- 12.7.5 Pfizer Recent Developments
- 12.8 Suzhou NoJieBeig (Pipeline)
- 12.8.1 Suzhou NoJieBeig (Pipeline) Company Information
- 12.8.2 Suzhou NoJieBeig (Pipeline) Business Overview
- 12.8.3 Suzhou NoJieBeig (Pipeline) Revenue in AAV Gene Therapy Injection Business (2021-2026)
- 12.8.4 Suzhou NoJieBeig (Pipeline) AAV Gene Therapy Injection Product Portfolio
- 12.8.5 Suzhou NoJieBeig (Pipeline) Recent Developments
- 12.9 Belief BioMed (Pipeline)
- 12.9.1 Belief BioMed (Pipeline) Company Information
- 12.9.2 Belief BioMed (Pipeline) Business Overview
- 12.9.3 Belief BioMed (Pipeline) Revenue in AAV Gene Therapy Injection Business (2021-2026)
- 12.9.4 Belief BioMed (Pipeline) AAV Gene Therapy Injection Product Portfolio
- 12.9.5 Belief BioMed (Pipeline) Recent Developments
- 12.10 Beijing Innovikang (Pipeline)
- 12.10.1 Beijing Innovikang (Pipeline) Company Information
- 12.10.2 Beijing Innovikang (Pipeline) Business Overview
- 12.10.3 Beijing Innovikang (Pipeline) Revenue in AAV Gene Therapy Injection Business (2021-2026)
- 12.10.4 Beijing Innovikang (Pipeline) AAV Gene Therapy Injection Product Portfolio
- 12.10.5 Beijing Innovikang (Pipeline) Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst